Customers tell us they want peace of mind so that if a consumer has their beverage across multiple day parts, they will have a large margin before hitting tolerance levels. Why beverage brands need to brace themselves The thirst for GLP-1 medication only looks set to increase among consumers with the launch of unfussy, non-injectable formats A pill version of the appetite-suppressing drug, Wegovy, was unveiled by pharma giant Novo Nordisk in January Eli Lilly & Co is preparing to debut its own oral version, Orforglipron, post-FDA approval later this year The total GLP-1 pill market is forecast to leap from $3.2bn in 2025 to 34.3 bn in 2031, a CAGR of 48.4% (GlobalData) (Source GlobalData) GLP-1 drink NPD outside the box Although, its not just traditional food and beverage companies developing tailored NPD
Check the plan year (ensure you are looking at the updated 2026 formulary) as coverage can change
Most individuals can benefit safely, but pregnant or breastfeeding women, people with known vitamin or nutrient sensitivities, or those with specific medical conditions should consult with a healthcare provider before receiving injections
The startup said its GLP-1 injectable drug, which is made in partnership with a manufacturer of compounded injectable medications, will have "consistent" availability
In addition, a 1% weight gain since discontinuation was significantly associated with a 2.3% (95% CI, 1.9%-2.8%) increased hazard of reinitiation for patients with type 2 diabetes and a 2.8% (95% CI, 2.4%-3.2%) increased hazard of reinitiation for patients without type 2 diabetes
Based upon our review of the literature available, more progress has been made in asthma compared to COPD or CF, but much work still remains
